Feasibility of adjuvant self-administered intravaginal 5-fluorouracil cream following primary treatment of cervical intraepithelial neoplasia grade 2 or 3 among women living with HIV in Kenya: study protocol for a pilot trial
Authors: Mungo Chemtai , Bukusi Elizabeth , Kirkland Grace E , Ogollah Cirillus , Rota Gershon , Omoto Jackton , Rahangdale Lisa 
Published: December 2023

AbstractBackgroundWomen living with HIV (WLWH), the majority of whom live in low- and middle-income countries (LMICs), are at higher risk of cervical precancer, known as cervical intraepithelial neoplasia (CIN), and are up to six times more likely to get cervical cancer. Current CIN treatment methods, primarily ablation or excision, have high treatment failure rates among WLWH, up to 30% for CIN grade 2 or 3 (CIN2/3) at 24 months following ablation. Without strong follow-up many WLWH with treatment failure are at risk of developing invasive cervical cancer, highlighting the urgent need for improved CIN treatment methods. Prior studies in high-income countries (HICs) have demonstrated that 5-Fluorouracil (5-FU) cream, an antimetabolite drug that is easily accessible in LMICs, can be used intravaginally as adjuvant therapy following primary CIN2/3 treatment in WLWH to reduce CIN2/3 recurrence. While the safety, acceptability, and efficacy of self-administered 5-FU for cervical precancer treatment has been demonstrated in HICs, it has not been studied among WLWH in LMICs who bear the greatest burden of cervical cancer.MethodsWe are conducting a Phase I pilot study investigating the feasibility of using 5-FU cream as an adjuvant, self-administered intravaginal therapy following cervical intraepithelial neoplasia grade 2/3 (CIN2/3) treatment among WLWH in Kenya (ClinicalTrials.govNCT05362955). Twelve participants will be enrolled in this single-arm study. Participants will self-administer 2g of 5% 5-FU cream intravaginally every other week for eight applications. The primary objective is to determine safety, defined as the type, frequency, and severity of adverse events (AEs) using a standardized grading scale. The secondary objectives are uptake, tolerability, adherence, and acceptability.ResultsThere are no results at this time as this is an ongoing study.DiscussionTo achieve the World Health Organization (WHO) 90/70/90 global cervical cancer elimination goals, which include 90% of women with cervical precancer adequately treated by 2030, it is essential to employ innovative and resource-appropriate strategies to improve cervical precancer treatment among WLWH. The use of 5-FU as adjuvant therapy following current screen & treat programs may be a feasible and scalable strategy to optimize outcomes in this high-risk group. This clinical trial will provide important feasibility data to inform future randomized efficacy trials in LMICs.Trial registrationClinicalTrials.govidentifier:NCT05362955Key messages regarding feasibilityWhat uncertainties existed regarding feasibility?There are no uncertainties to report yet as the study is ongoing.What are the key feasibility findings?There are no key feasibility findings as the study is ongoing.What are the implications of the feasibility findings for the design of the main study?Feasibility findings from this trial that will inform the design of the future study include safety findings - frequency and severity of adverse events, which may necessitate a different dosing schedule for the main study, adherence findings - if low levels of adherence to self-administered therapies are established, the authors will work on designing strategies to improve adherence prior to moving to a larger study. Finally, acceptability findings including the levels of male partner support of the treatment will inform future study efforts.